Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03963401
Previous Study | Return to List | Next Study

A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03963401
Recruitment Status : Recruiting
First Posted : May 24, 2019
Last Update Posted : August 7, 2019
Sponsor:
Information provided by (Responsible Party):
Pfizer

Tracking Information
First Submitted Date  ICMJE May 15, 2019
First Posted Date  ICMJE May 24, 2019
Last Update Posted Date August 7, 2019
Actual Study Start Date  ICMJE June 13, 2019
Estimated Primary Completion Date July 20, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 23, 2019)
The proportion of subjects achieving an ACR20 response [ Time Frame: Week 16 ]
The proportion of subjects achieving an American College of Rheumatology 20 (ACR20) response at Week 16.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03963401 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: May 23, 2019)
  • The proportion of TNF-naive subjects achieving an ACR20 response [ Time Frame: Week 16 ]
    The proportion of subjects achieving an ACR20 response at Week 16 in the subgroup of subjects who are TNF-alpha inhibitor naïve.
  • The proportion of subjects achieving an ACR20 response [ Time Frame: Week 2, 4, 8, 12, 20, 28, 36, 44, and 52 ]
    The proportion of subjects achieving an ACR20 response at all treatment timepoints except Week 16
  • The proportion of subjects achieving an ACR50 response [ Time Frame: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    The proportion of subjects achieving an ACR50 response at all treatment timepoints
  • The proportion of subjects achieving an ACR70 response [ Time Frame: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    The proportion of subjects achieving an ACR70 response at all treatment timepoints
  • Change from baseline in the ACR response criteria components [ Time Frame: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    Change from baseline in the ACR response criteria components (Tender/painful joint count, Swollen joint count, Patient's Assessment of Arthritis Pain, Patient's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, Health Assessment Questionnaire [HAQ] disability index [DI], and hsCRP)
  • The proportion of subjects achieving a Psoriasis Area and Severity Index 75/90/100 (PASI75/90/100) response [ Time Frame: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    The proportion of subjects achieving a Psoriasis Area and Severity Index 75/90/100 (PASI75/90/100) response at all treatment timepoints
  • Change from baseline in the enthesitis score using the Spondyloarthritis Research Consortium of Canada [SPARCC] Enthesitis Index. [ Time Frame: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    Change from baseline in the enthesitis score using the Spondyloarthritis Research Consortium of Canada [SPARCC] Enthesitis Index.
  • Change from baseline in the enthesitis score using the Leeds Enthesitis Index. [ Time Frame: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    Change from baseline in the enthesitis score using the Leeds Enthesitis Index.
  • Change from baseline in the Dactylitis Severity Score [ Time Frame: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    Change from baseline in the Dactylitis Severity Score at all treatment timepoints
  • Change from baseline in the Nail Psoriasis Severity Index (NAPSI) Score [ Time Frame: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    Change from baseline in the Nail Psoriasis Severity Index (NAPSI) Score at all treatment timepoints
  • Change from baseline in the Patient's Global Joint and Skin Assessment Visual Analog Scale (PGJS VAS) [ Time Frame: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    Change from baseline in the Patient's Global Joint and Skin Assessment Visual Analog Scale (PGJS VAS) at all treatment timepoints. Scale will be 100 mm in length.
  • Change from baseline in the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT Fatigue) [ Time Frame: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    Change from baseline in the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT Fatigue) at all treatment timepoints
  • Change from baseline in the Short Form 36 Health Survey (SF 36) Version 2, Acute [ Time Frame: Week 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    Change from baseline in the Short Form 36 Health Survey (SF 36) Version 2, Acute, at all treatment timepoints except Week 2
  • The proportion of subjects achieving Minimal Disease Activity (MDA) and Very Low Disease Activity (VLDA) response [ Time Frame: Week 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    The proportion of subjects achieving Minimal Disease Activity (MDA) and Very Low Disease Activity (VLDA) response at all treatment timepoints except Week 2
  • Change from baseline in the Disease Activity Index for Reactive Arthritis/PsA (DAREA/DAPSA) [ Time Frame: Week 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    Change from baseline in the Disease Activity Index for Reactive Arthritis/PsA (DAREA/DAPSA)
  • The proportion of subjects achieving the Psoriatic Arthritis Response Criteria (PsARC) [ Time Frame: Week 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    The proportion of subjects achieving the Psoriatic Arthritis Response Criteria (PsARC) at all treatment timepoints except Week 2
  • Change from baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) [ Time Frame: Week 4, 8, 12, 16, 20, 28, 36, 44, and 52 ]
    Change from baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at all treatment timepoints except Week 2
  • Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline through Week 56 ]
  • Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs [ Time Frame: Baseline through Week 56 ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
Official Title  ICMJE A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PF-06700841 TO EVALUATE THE EFFICACY AT 16 WEEKS AND TO EVALUATE THE SAFETY AND EFFICACY UP TO 1 YEAR IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
Brief Summary This is a 52 week Phase 2b study designed to evaluate the efficacy at 16 weeks and to evaluate the safety and efficacy up to 1 year in subjects with active psoriatic arthritis.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Psoriatic Arthritis
Intervention  ICMJE
  • Drug: PF-06700841
    Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
  • Other: Placebo
    Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
Study Arms  ICMJE
  • Experimental: PF-06700841 60 mg once daily
    PF-06700841 60 mg once daily for 52 weeks
    Intervention: Drug: PF-06700841
  • Experimental: PF-06700841 30 mg once daily
    PF-06700841 30 mg once daily for 52 weeks
    Intervention: Drug: PF-06700841
  • Experimental: PF-06700841 10 mg once daily followed by 60 mg once daily
    PF-06700841 10 mg once daily for 16 weeks, followed by 60 mg once daily until Week 52
    Intervention: Drug: PF-06700841
  • Experimental: PF-06700841 10 mg once daily followed by 30 mg once daily
    PF-06700841 10 mg once daily for 16 weeks, followed by 30 mg once daily until Week 52
    Intervention: Drug: PF-06700841
  • Placebo Comparator: Placebo once daily followed by 60 mg once daily
    Placebo once daily for 16 weeks, followed by PF-06700841 60 mg once daily until Week 52
    Intervention: Other: Placebo
  • Placebo Comparator: Placebo once daily followed by 30 mg once daily
    Placebo once daily for 16 weeks, followed by PF-06700841 30 mg once daily until Week 52
    Intervention: Other: Placebo
Publications * Banfield C, Scaramozza M, Zhang W, Kieras E, Page KM, Fensome A, Vincent M, Dowty ME, Goteti K, Winkle PJ, Peeva E. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis. J Clin Pharmacol. 2018 Apr;58(4):434-447. doi: 10.1002/jcph.1046. Epub 2017 Dec 21.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 23, 2019)
196
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE April 27, 2021
Estimated Primary Completion Date July 20, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Active arthritis at screening/baseline as indicated by >/= 3 tender/painful and 3 swollen joints.
  • Active plaque psoriasis at screening and baseline.

Exclusion Criteria:

  • Non-plaque forms of psoriasis (with exception of nail psoriasis).
  • History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com
Listed Location Countries  ICMJE Australia,   Lithuania,   Poland
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03963401
Other Study ID Numbers  ICMJE B7931030
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date August 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP